Biotech Values

[DewDiligence]

TCON obtains SPA for TRC105 in angiosarcoma:

http://finance.yahoo.com/news/tracon-pharmaceuticals-receives-special-protocol-130000684.html

TRACON intends to conduct the Phase 3 TAPPAS trial (a randomized Phase 3 trial of TRC105 And Pazopanib versus Pazopanib alone in patients with advanced AngioSarcoma) at sites in both the United States and Europe. This one-to-one randomized trial of [v]TRC105 in combination with Votrient (pazopanib) versus Votrient alone[/v] will initially enroll 124 patients.

The trial features an adaptive design that, based on an interim analysis, can allow for sample size re-estimation up to a maximum of 200 patients, as well as possible enrichment of more responsive patients with cutaneous angiosarcoma. The primary endpoint of the trial is progression-free survival (PFS), with overall survival (OS) as a secondary endpoint.

The clinicaltrials.gov listing is at : https://www.clinicaltrials.gov/ct2/show/NCT02979899 . Topline results are expected in Sep 2018.